Does TAGRAXOFUSP-ERZS Cause Tumour lysis syndrome? 21 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Tumour lysis syndrome have been filed in association with TAGRAXOFUSP-ERZS. This represents 4.8% of all adverse event reports for TAGRAXOFUSP-ERZS.
21
Reports of Tumour lysis syndrome with TAGRAXOFUSP-ERZS
4.8%
of all TAGRAXOFUSP-ERZS reports
9
Deaths
3
Hospitalizations
How Dangerous Is Tumour lysis syndrome From TAGRAXOFUSP-ERZS?
Of the 21 reports, 9 (42.9%) resulted in death, 3 (14.3%) required hospitalization.
Is Tumour lysis syndrome Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAGRAXOFUSP-ERZS. However, 21 reports have been filed with the FAERS database.
What Other Side Effects Does TAGRAXOFUSP-ERZS Cause?
Capillary leak syndrome (110)
Pyrexia (45)
Death (36)
Disease progression (33)
Thrombocytopenia (26)
Blood albumin decreased (24)
Acute kidney injury (23)
Off label use (23)
Weight increased (22)
Transaminases increased (21)
What Other Drugs Cause Tumour lysis syndrome?
VENETOCLAX (1,057)
RITUXIMAB (1,056)
CYCLOPHOSPHAMIDE (918)
VINCRISTINE (832)
DOXORUBICIN (803)
DEXAMETHASONE (795)
ETOPOSIDE (553)
PREDNISONE (550)
CYTARABINE (407)
CARBOPLATIN (337)
Which TAGRAXOFUSP-ERZS Alternatives Have Lower Tumour lysis syndrome Risk?
TAGRAXOFUSP-ERZS vs TAHOR
TAGRAXOFUSP-ERZS vs TALAZOPARIB
TAGRAXOFUSP-ERZS vs TALC
TAGRAXOFUSP-ERZS vs TALIGLUCERASE ALFA
TAGRAXOFUSP-ERZS vs TALIMOGENE LAHERPAREPVEC